381 related articles for article (PubMed ID: 24004656)
21. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
Giannì M; de Thé H
Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
[TBL] [Abstract][Full Text] [Related]
22. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H
Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903
[TBL] [Abstract][Full Text] [Related]
23. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
24. Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Noh EK; Kim H; Park MJ; Baek JH; Park JH; Cha SJ; Won JH; Min YJ
Leuk Res; 2010 Nov; 34(11):1501-5. PubMed ID: 20226526
[TBL] [Abstract][Full Text] [Related]
25. [Effects of arsenic trioxide on the subcellular localization of PML/PML-RARalpha protein in leukemic cells].
Ni J; Chen G; Zhu J; Zhong H; Tang W; Li X; Xiong S; Shen Z; Chen S; Wang Z; Chen L
Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):32-4. PubMed ID: 15622748
[TBL] [Abstract][Full Text] [Related]
26. Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.
Lallemand-Breitenbach V; Zhu J; Puvion F; Koken M; Honoré N; Doubeikovsky A; Duprez E; Pandolfi PP; Puvion E; Freemont P; de Thé H
J Exp Med; 2001 Jun; 193(12):1361-71. PubMed ID: 11413191
[TBL] [Abstract][Full Text] [Related]
27. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
28. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
[TBL] [Abstract][Full Text] [Related]
29. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.
Ora I; Bondesson L; Jönsson C; Ljungberg J; Pörn-Ares I; Garwicz S; Pâhlman S
Biochem Biophys Res Commun; 2000 Oct; 277(1):179-85. PubMed ID: 11027660
[TBL] [Abstract][Full Text] [Related]
30. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
Guo W; Wang H; Zhao W; Zhu J; Ju B; Wang X
Chin Med J (Engl); 2001 Jan; 114(1):30-4. PubMed ID: 11779431
[TBL] [Abstract][Full Text] [Related]
31. As2O3-induced c-Src/EGFR/ERK signaling is via Sp1 binding sites to stimulate p21WAF1/CIP1 expression in human epidermoid carcinoma A431 cells.
Liu ZM; Huang HS
Cell Signal; 2006 Feb; 18(2):244-55. PubMed ID: 15961274
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
33. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
34. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
[TBL] [Abstract][Full Text] [Related]
35. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
[TBL] [Abstract][Full Text] [Related]
36. [Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].
Jia PM; Zhu Q; Yu Y; Chen GQ; Chen SJ; Chen Z; Wang ZY; Tong JH
Ai Zheng; 2002 Apr; 21(4):337-40. PubMed ID: 12452006
[TBL] [Abstract][Full Text] [Related]
37. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.
Hayakawa F; Privalsky ML
Cancer Cell; 2004 Apr; 5(4):389-401. PubMed ID: 15093545
[TBL] [Abstract][Full Text] [Related]
39. Restoration of promyelocytic leukemia protein-nuclear bodies in neuroblastoma cells enhances retinoic acid responsiveness.
Yu JH; Nakajima A; Nakajima H; Diller LR; Bloch KD; Bloch DB
Cancer Res; 2004 Feb; 64(3):928-33. PubMed ID: 14871822
[TBL] [Abstract][Full Text] [Related]
40. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
